Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy
Authors
Keywords
-
Journal
CANCER
Volume 119, Issue 2, Pages 454-462
Publisher
Wiley
Online
2012-07-04
DOI
10.1002/cncr.27739
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection
- (2011) Shishir K. Maithel et al. ANNALS OF SURGICAL ONCOLOGY
- Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer
- (2011) D. Ansari et al. BRITISH JOURNAL OF SURGERY
- Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer
- (2011) Jenny Andrews et al. CANCER JOURNAL
- Ribonucleotide Reductase Small Subunit M2B Prognoses Better Survival in Colorectal Cancer
- (2011) X. Liu et al. CANCER RESEARCH
- Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma
- (2011) I. Borbath et al. EUROPEAN JOURNAL OF CANCER
- Ribonucleotide Reductase M1 Expression in Intrahepatic Cholangiocarcinoma
- (2011) Toshifumi Wakai et al. HEPATO-GASTROENTEROLOGY
- Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma
- (2010) Yoshiaki Murakami et al. ANNALS OF SURGICAL ONCOLOGY
- Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
- (2010) D. Santini et al. CURRENT CANCER DRUG TARGETS
- Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO)
- (2010) Domenico Alvaro et al. DIGESTIVE AND LIVER DISEASE
- Management of Gallbladder Cancer
- (2010) Shiva Jayaraman et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- National Trends in the Management and Survival of Surgically Managed Gallbladder Adenocarcinoma Over 15 years: A Population-Based Analysis
- (2010) Skye C. Mayo et al. JOURNAL OF GASTROINTESTINAL SURGERY
- The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer
- (2010) Lars Petter Jordheim et al. LANCET ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current Management of Gallbladder Carcinoma
- (2010) A. X. Zhu et al. ONCOLOGIST
- Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer
- (2009) Gabriella Ferrandina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now